Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
TLDR; The Value of Drugs for Rare Disease Indications May Be Higher Than You Think – Assets for Neurodevelopmental Disorders Alone May Be Worth Beyond USD $420B.
Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease
Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders
Congenica Completes $50m Series C Funding Round to Advance Clinical Genomic Analysis Software and Data Platform
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics